[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Article
April 1994

Prophylaxis of Primary Cytomegalovirus Disease in Renal Transplant RecipientsA Trial of Ganciclovir vs Immunoglobulin

Author Affiliations

From the Department of Surgery, Section of Transplantation, Albany (NY) Medical College.

Arch Surg. 1994;129(4):443-447. doi:10.1001/archsurg.1994.01420280121016
Abstract

Objective:  To compare the efficacy, safety, and cost of prophylactic low-dose ganciclovir with that of immunoglobulin in renal transplant recipients at risk for primary cytomegalovirus (CMV) disease.

Design and Setting:  A prospective, randomized trial at a 650-bed tertiary medical center hospital.

Patients:  Fifty-one consecutive CMV-seronegative patients who received renal allografts from seropositive donors between March 1990 and April 1992.

Main Outcome Measures:  Patient and allograft survival, and the incidence and severity of CMV disease.

Intervention:  Cytomegalovirus prophylaxis with seven doses of intravenous immunoglobulin for 6-week periods (group 1, n=27) or low-dose intravenous ganciclovir for 3 weeks (group 2, n=24). Results were compared with those obtained in 23 CMV-seronegative historical positive donors between 1987 and 1989, and who did n-positive donors between 1987 and 1989, and who did not receive prophylaxis for CMV (group 3).

Results:  Both prophylactic regimens significantly reduced the incidence of invasive CMV infection (P<.05) and were well tolerated. However, the cost of ganciclovir ($350 per patient) was substantially less than that of immunoglobulin ($4000 per patient).

Conclusions:  These data suggest that prophylactic ganciclovir therapy provides a cost-effective approach toward significantly improving the outcome of renal transplantation in recipients at risk for primary CMV disease.(Arch Surg. 1994;129:443-447)

References
1.
Rubin RH, Tolkoff-Rubin NE.  Antimicrobial strategies in the care of organ transplant recipients . Antimicrob Agents Chemother . 1993;37:619-624.Article
2.
Rubin RH, Tolkoff-Rubin NE.  The impact of infections on the outcome of transplantation . Transplant Proc . 1991;23:2068-2074.
3.
Chatterjee SN, Fiala M, Weiner J, et al.  Primary cytomegalovirus and opportunistic infections . JAMA . 1978;240:2446-2449.Article
4.
Fryd DS, Peterson PK, Ferguson RM, et al.  Cytomegalovirus as a risk factor in renal transplantation . Transplantation . 1980;30:436-439.Article
5.
Rubin RH.  Impact of cytomegalovirus infection on organ transplant recipients . Rev Infect Dis . 1990;12( (suppl 7) ):5754.
6.
Hibberd PL, Tolkoff-Rubin NE, Cosimi AB, et al.  Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3 . Transplantation . 1992;53:63-72.Article
7.
Rubin RH, Tolkoff-Rubin NE.  Infection: the new problems . Transplant Proc . 1989;21:1440-1445.
8.
Martin M.  Cytomegalovirus prophylaxis in solid organ transplantation . Transpl Sci . 1992;2:83-87.
9.
Snydman DR.  Cytomegalovirus infection in solid organ transplantation . Transpl Rev . 1990;4:59-67.Article
10.
Ho M, Suwansirikul S, Dowling JN, et al.  The transplanted kidney as a source of cytomegalovirus infection . N Engl J Med . 1975;293:1109-1112.Article
11.
Cheeseman SH, Rubin RH, Stewart JA, et al.  Controlled clinical trial of prophylactic human-leukocyte interferon in renal transplantation . N Engl J Med . 1979; 300:1345-1349.Article
12.
Snydman DR, Werner BG, Heinze-Lacey B, et al.  Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal transplant recipients . N Engl J Med . 1987;317:1049-1054.Article
13.
Conti DJ, Freed BM, Lempert N.  Prophylactic immunoglobulin therapy improves the outcome of renal transplantation in recipients at risk for primary cytomegalovirus disease . Transpl Proc . 1993;25:1421-1422.
14.
Steinmuller DR, Graneto D, Swift C, et al.  Use of intravenous immunoglobulin prophylaxis for primary cytomegalovirus infection post living-related donor renal transplantation . Transpl Proc . 1989;21:2069-2071.
15.
Balfour HH, Chase BA, Stapelton JT, et al.  A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allograft . N Engl J Med . 1989;320:1381-1387.Article
16.
Fletcher CV, Englund JA, Edelman CK, et al.  The pharmacologic basis for high-dose oral acyclovir prophylaxis of cytomegalovirus disease in renal allograft recipients . Antimicrob Agents Chemother . 1991;35:938-943.Article
17.
Vasquez EM, Sanchez J, Pollak R, et al.  High-dose oral acyclovir prophylaxis for primary cytomegalovirus infection in seronegative renal allograft recipients . Transplantation . 1993;55:448-450.Article
18.
Nicol D, MacDonald AS, Bitter-Suermann H, et al. Combination prophylaxis therapy with CMV hyperimmune globulin and acyclovir reduces the risk of primary CMV disease in renal transplant recipients. Presented at the 18th Annual Meeting of the American Society of Transplant Surgeons; May 29, 1992; Chicago, Ill.
19.
Fassbinder W, Ernst W, Hanke P, et al.  Cytomegalovirus infections after renal transplantation . Transplant Proc . 1986;18:1393-1396.
20.
Merigan TC, Renlund DG, Keay S, et al.  A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation . N Engl J Med . 1992; 326:1182-1186.Article
21.
Bailey TC, Trulock EP, Ettenger NA, et al.  Failure of prophylactic ganciclovir to prevent cytomegalovirus disease in recipients of lung transplants . J Infect Dis . 1992;165:548-552.Article
22.
Ho M, Dummer JS.  Risk factors and approaches to infections in transplant recipients . In: Mandell GJ, Douglas RG, Bennett JE, eds. Principles and Practice of Infectious Disease . New York, NY: Churchill Livingstone; 1990:2284-2291.
23.
Hibberd PL, Rubin RH, Conti DJ, et al. Pre-emptive ganciclovir for prevention of symptomatic cytomegalovirus disease in the CMV seropositive renal transplant recipient treated with anti-lymphocyte antibody. Presented at the 12th Annual Meeting of the American Society of Transplant Physicians; May 17, 1993; Houston, Tex.
×